Genprex to Combine Reqorsa With Checkpoint, EGFR Inhibitors in Lung Cancer Studies
Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca’s Tagrisso) or pembrolizumab (Merck’s Keytruda).
original article: Genprex to Combine Reqorsa With Checkpoint, EGFR Inhibitors in Lung Cancer Studies | Precision Medicine Online